Related Experiment Videos
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned
Philip J Clements1, James R Seibold, Daniel E Furst
1Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA 90095-1670, USA. pclements@mednet.ucla.edu
Seminars in Arthritis and Rheumatism
|February 24, 2004
Summary
This randomized controlled trial in systemic sclerosis (SSc) found d-penicillamine ineffective but highlighted valid outcome measures. Learnings from this trial inform future clinical trial design and patient function assessments.
Area of Science:
- Rheumatology
- Clinical Trial Design
- Systemic Sclerosis Research
Background:
- Systemic sclerosis (SSc) is a complex autoimmune disease requiring effective treatments.
- Randomized controlled trials (RCTs) are crucial for evaluating new therapies in SSc.
- Early diffuse SSc presents unique challenges for clinical trial management.
Purpose of the Study:
- To review lessons learned from a randomized controlled trial (RCT) evaluating d-penicillamine in early diffuse SSc.
- To assess the efficacy of high-dose versus low-dose d-penicillamine in treating early diffuse SSc.
- To identify important findings regarding response measures, trial design, conduct, and analysis.
Main Methods:
- A randomized controlled trial (RCT) involving 134 patients with early (< or =18 months) diffuse SSc.
- Comparison of high-dose (822 mg daily) versus low-dose (120 mg every other day) d-penicillamine.
- Regular patient follow-up for up to 4 years, with pooled data analysis due to initial lack of efficacy.
Main Results:
- The RCT demonstrated that clinical trials for disease-modifying interventions can be successfully conducted in SSc.
- No significant efficacy was found for either high-dose or low-dose d-penicillamine in early diffuse SSc.
- Skin score and the Health Assessment Questionnaire Disability Index (HAQ-DI) were validated as outcome predictors and response measures.
Conclusions:
- Therapeutically negative trials can still yield valuable insights into trial design, outcome measures, and patient function.
- The study suggests using placebo controls in SSc trials until a truly effective active control is identified.
- Careful evaluation of data from negative trials can inform future research and improve patient care in SSc.